The present disclosure relates to bismuth-thiol compounds such as bismuth-1,2-dithiane (BisEDT) for use in treating, preventing and/or reducing the effects of osteomyelitis in a subject in need thereof.

The present disclosure relates to bismuth-thiol compounds such as bismuth-1,2-dithiane (BisEDT) for use in treating, preventing and/or reducing the effects of osteomyelitis in a subject in need thereof.

Described herein are compositions, methods, and devices for relief of a cough, cold, sore throat, or allergy, or a related symptom. Also described herein are compositions, methods, and devices for the prevention, treatment and/or amelioration of a digestive illness or digestive discomfort, or a related symptom of either. Such compositions may be in the form of a liquid composition and include a plurality of pharmaceutical ingredients and a plurality of botanical ingredients.

Described herein are compositions, methods, and devices for relief of a cough, cold, sore throat, or allergy, or a related symptom. Also described herein are compositions, methods, and devices for the prevention, treatment and/or amelioration of a digestive illness or digestive discomfort, or a related symptom of either. Such compositions may be in the form of a liquid composition and include a plurality of pharmaceutical ingredients and a plurality of botanical ingredients.

Described herein are compositions, methods, and devices for relief of a cough, cold, sore throat, or allergy, or a related symptom. Also described herein are compositions, methods, and devices for the prevention, treatment and/or amelioration of a digestive illness or digestive discomfort, or a related symptom of either. Such compositions may be in the form of a liquid composition and include a plurality of pharmaceutical ingredients and a plurality of botanical ingredients.

Disclosed herein are methods of treating a cancer cell that include contacting a cancer cell with a compound having the structure of formula (I) ##STR00001##
M is Pt, Pd or Ni; Q is As, Sb or Bi; Z.sup.1 is N; Z.sup.2 is O or S; L.sup.1 and L.sup.2 are independently C(O), CR.sup.1 or CR.sup.2; X is a Lewis base; Y.sup.1 and Y.sup.2 are independently selected from OR.sup.3, OR.sup.4, SR.sup.3 and SR.sup.4, wherein R.sup.1 and R.sup.2 are independently selected from hydrogen, halogen, cyano, keto, ester, ether, thiol, thioether, thioester, imino, C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C.sub.3-C.sub.15 cycloalkyl, heteroaryl, and C.sub.3-C.sub.15 heterocycloalkyl; and R.sup.3 and R.sup.4 are independently selected from hydrogen, C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C.sub.3-C.sub.15 cycloalkyl, heteroaryl, and C.sub.3-C.sub.15 heterocycloalkyl.

Disclosed herein are methods of treating a cancer cell that include contacting a cancer cell with a compound having the structure of formula (I) ##STR00001##
M is Pt, Pd or Ni; Q is As, Sb or Bi; Z.sup.1 is N; Z.sup.2 is O or S; L.sup.1 and L.sup.2 are independently C(O), CR.sup.1 or CR.sup.2; X is a Lewis base; Y.sup.1 and Y.sup.2 are independently selected from OR.sup.3, OR.sup.4, SR.sup.3 and SR.sup.4, wherein R.sup.1 and R.sup.2 are independently selected from hydrogen, halogen, cyano, keto, ester, ether, thiol, thioether, thioester, imino, C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C.sub.3-C.sub.15 cycloalkyl, heteroaryl, and C.sub.3-C.sub.15 heterocycloalkyl; and R.sup.3 and R.sup.4 are independently selected from hydrogen, C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C.sub.3-C.sub.15 cycloalkyl, heteroaryl, and C.sub.3-C.sub.15 heterocycloalkyl.

A method of producing a liquid pharmaceutical suspension by mixing magnesium aluminum silicate, gellan gum, bismuth subsalicylate, and methyl cellulose.

A method of producing a liquid pharmaceutical suspension by mixing magnesium aluminum silicate, gellan gum, bismuth subsalicylate, and methyl cellulose.

Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections.